Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

YDES vs VRXA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

YDES Wins Head-to-Head Institutional Verdict (2–1 across 6 Pillars · 7–1 Matrix Metrics)

YDES Overall Winner 6-Pillar Tally: YDES 2 – 1 VRXA (3 Tie) Matrix Metrics: YDES 7 – 1 VRXA

As of Nov 20, 2026, YD Bio Limited (YDES) is the stronger overall head-to-head candidate over VRXA (VRXA) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). YDES carries a Unified Composite Score of 49.0/100 (HOLD) at $4.83 (N/M Forward P/E, -528.7% operating margin), whereas VRXA carries 41.6/100 (SELL) at $1.04 (N/M Forward P/E, N/A operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About YDES vs VRXA
YDES NASDAQ Head-to-Head Winner
YD Bio Limited Ordinary Shares
Services-Medical Laboratories
$4.83
+5.92% 1D
Market Cap $323.0M
TTM Revenue $1.2M
Forward P/E N/M
Beta / 30D Vol -0.07β · 139% Vol
Unified Composite Score
49.0 / 100 HOLD
Tech 31.0 Fund 35.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 44
RSI-14: 43.6 · SMA20: $5.73 · SMA50: $5.60
VRXA US Equity
VRXA
Institutional Equity
$1.04
+0.97% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.16β · 104% Vol
Unified Composite Score
41.6 / 100 SELL
Tech 30.0 Fund 41.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 46
RSI-14: 46.0 · SMA20: $1.04 · SMA50: $1.17

6-Pillar Scorecard Institutional Category Breakdown (YDES 2 – 1 VRXA)

Columns: Metric · YDES · VRXA
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale YDES
Revenue Growth (YoY) +314.9% N/A
Earnings Growth (YoY) +0.0% N/A
TTM Revenue (USD) $1.2M N/A
Market Cap $323.0M N/A
3. Profitability & Quality YDES
Gross Margin 29.6% N/A
Operating Margin -528.7% N/A
Net Profit Margin 24.7% N/A
Return on Equity (ROE) -42.7% N/A
4. Balance Sheet & Cash Flow VRXA
Cash Generation (TTM) -$6.3M EBITDA N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $0.06 Book/Sh · -42.7% ROE N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: YDES (7) vs VRXA (1)
Institutional Metric YDES VRXA Criterion Row Edge
Market Capitalization
Scale
$323.0M N/A Larger Scale YDES
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+314.9% N/A Higher Growth YDES
Operating Margin (TTM)
Profitability
-528.7% N/A Higher Margin YDES
Net Profit Margin
Profitability
24.7% N/A Higher Margin YDES
Return on Equity (ROE)
Capital Efficiency
-42.7% N/A Higher ROE YDES
52-Week Range Position
Momentum
22% ($2–$16) 0% ($1–$27) Stronger Trend YDES
Beta / 30D Volatility
Risk Regime
-0.07β · 139% Vol 1.16β · 104% Vol Lower Realized Risk VRXA
Unified Institutional Score
Composite Signal
49.0 / 100 (HOLD) 41.6 / 100 (SELL) Higher Composite YDES
Trailing 12M Revenue (USD)
Operating Scale
$1.2M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
29.6% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$6.3M EBITDA ($0.06 Book/Sh · -42.7% ROE) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon YDES +12.95 pp
YDES: +13.92% · VRXA: +0.97%
3M Horizon YDES +45.22 pp
YDES: +3.65% · VRXA: -41.57%
6M Horizon YDES +144.42 pp
YDES: +48.62% · VRXA: -95.8%
1Y Horizon YDES +144.42 pp
YDES: +48.62% · VRXA: -95.8%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on YDES vs VRXA. Trailing 12-month operating profitability (YDES -528.7% vs VRXA N/A) and valuation multiples (YDES N/M vs VRXA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

YDES ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.2M
Gross Margin29.6%
Op. Margin-528.7%
ROE / Fwd P/E-42.7% · N/M
VRXA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
YDES UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact YDES Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VRXA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact VRXA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
YDES Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $323.0M market capitalization and -528.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
VRXA Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ YDES vs VRXA Key Questions & Quantitative Answers

As of Nov 20, 2026, YD Bio Limited (YDES) is the stronger overall head-to-head candidate over VRXA (VRXA) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). YDES carries a Unified Composite Score of 49.0/100 (HOLD) at $4.83 (N/M Forward P/E, -528.7% operating margin), whereas VRXA carries 41.6/100 (SELL) at $1.04 (N/M Forward P/E, N/A operating margin). Technically, YDES sits in a Neutral phase (RSI 43.6, UNCLASSIFIED options structure) and VRXA sits in a Neutral phase (RSI 46.0, UNCLASSIFIED options structure).

YDES leads the Growth & Scale pillar: YDES posts +314.9% YoY revenue growth and +0.0% YoY earnings growth on $1.2M TTM revenue (29.6% gross margin, -528.7% operating margin), compared with VRXA at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, YDES generates $1.2M in USD-normalized revenue versus N/A for VRXA. In operating R&D and SG&A reinvestment, YDES deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VRXA.

YDES and VRXA trade at balanced relative valuation multiples. YDES trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin), whereas VRXA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against YDES (-42.7% ROE) versus VRXA (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, YDES carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.07β · 139% Vol realized risk). By comparison, VRXA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.16β · 104% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.